Obliterative Bronchiolitis – A Complete Patient Guide

Overview

Obliterative bronchiolitis (OB), also called constrictive bronchiolitis, is a rare, progressive disease that causes scarring and narrowing of the small airways (bronchioles). The scarring “obliterates” the lumen, making it difficult for air to move in and out of the lungs. Unlike asthma or chronic obstructive pulmonary disease (COPD), the airflow limitation in OB is usually irreversible.

OB can affect anyone, but certain groups are at higher risk:

• Adults who have undergone lung or bone‑marrow transplantation (post‑transplant OB is the most common form).
• Individuals with a history of severe inhalational injury (e.g., exposure to toxic fumes, gases, or chemicals).
• Patients with connective‑tissue diseases such as rheumatoid arthritis, Sjögren’s syndrome, or systemic lupus erythematosus.
• People with a prior viral infection (especially adenovirus) during childhood, which can lead to “post‑infectious OB”.

Because OB is uncommon, precise prevalence figures are limited. In the United States, post‑lung‑transplant bronchiolitis obliterans syndrome (BOS) occurs in 5–10 % of recipients within the first 2 years after transplant, and up to 30 % after 5 years (Mayo Clinic, 2023). For non‑transplant cases, estimates range from 1–5 cases per million people per year (World Health Organization, 2022).

Symptoms

Symptoms develop gradually and often mimic other respiratory illnesses, which can delay diagnosis. Below is a comprehensive list with brief explanations.

Respiratory Symptoms

• Progressive shortness of breath (dyspnea): Initially occurs during exertion; later may be present at rest.
• Dry, non‑productive cough: Persistent, often worse at night.
• Wheezing or "rhonchi": High‑pitched sounds due to narrowed bronchioles.
• Sensation of chest tightness: Not typical of asthma and does not improve markedly with a bronchodilator.
• Decreased exercise tolerance: Simple activities such as climbing stairs become difficult.

Systemic/General Symptoms

• Fatigue – due to chronic low‑grade hypoxia.
• Weight loss – may result from increased work of breathing.
• Low‑grade fever – uncommon, but can occur during acute exacerbations or with infection.

Red‑Flag Symptoms (indicating possible acute worsening)

• Sudden increase in shortness of breath.
• Rapidly worsening cough with yellow/green sputum.
• Chest pain that is sharp and worsens with breathing.
• Bluish discoloration of lips or fingertips (cyanosis).

Causes and Risk Factors

OB is not a single disease but a pattern of airway injury that can be triggered by several mechanisms.

1. Post‑Transplant Immune‑Mediated Injury

The most frequent cause is chronic graft‑versus‑host disease (GVHD) after allogeneic hematopoietic stem‑cell transplantation (HSCT) or chronic rejection after lung transplantation. The immune system attacks the donor lung tissue, leading to fibro‑proliferative scarring.

2. Toxic Inhalational Exposures

Exposure to high‑concentration gases or chemicals such as:

• Chlorine, ammonia, or sulfates (industrial accidents).
• Sulfur mustard, chlorine gas, or pyrethroids (military or terrorism settings).
• Flavoring chemicals (e.g., diacetyl) used in e‑cigarettes or “popcorn lung” outbreaks.

3. Infections

Severe viral infections (adenovirus, measles, influenza) in children or adults can damage the bronchiolar epithelium and trigger a fibrotic response.

4. Autoimmune/Connective‑Tissue Diseases

Systemic inflammation associated with rheumatoid arthritis, systemic sclerosis, or inflammatory bowel disease may involve the small airways.

5. Medications & Radiation

Certain chemotherapy agents (e.g., cyclophosphamide), radiation therapy to the chest, and newer immunotherapies have been linked to OB in isolated case reports.

Risk Factors

• History of lung or bone‑marrow transplantation.
• Prolonged exposure to inhaled toxins (occupational or environmental).
• Underlying autoimmune disease.
• Older age (>50 y) in transplant populations (immune senescence).
  *Note: In children, post‑infectious OB is the predominant form.

Diagnosis

Because symptoms overlap with asthma, COPD, and infectious bronchiolitis, a systematic approach is required.

1. Detailed History & Physical Exam

• History of transplantation, toxic exposure, or recent severe infection.
• Examination may reveal wheezes, prolonged expiratory phase, and signs of hypoxia (e.g., digital clubbing in advanced disease).

2. Pulmonary Function Tests (PFTs)

Typical findings:

• Obstructive pattern – reduced FEV₁ (forced expiratory volume in 1 second) with a normal or increased FVC (forced vital capacity).
• Marked decline in FEV₁ over 3 months (>10 % drop) suggests progression.
• Reduced diffusion capacity (DLCO) may be present.

3. Imaging

• High‑Resolution CT (HRCT): The imaging gold standard. Findings include:
• Air‑trapping on expiratory scans (mosaic attenuation).
• Bronchial wall thickening and “tree‑in‑bud” nodules.
• Tracheobronchial stenosis in advanced disease.
• Chest X‑ray: Often normal or shows hyperinflation; limited utility.

4. Bronchoscopy with Biopsy

Transbronchial or surgical lung biopsy provides definitive histologic confirmation: concentric fibrosis of the bronchiolar submucosa leading to lumen obliteration. Due to procedural risk, biopsy is reserved for atypical cases where imaging and clinical picture are inconclusive.

5. Laboratory Tests

Used mainly to identify underlying causes:

• Autoimmune panel (ANA, RF, anti‑CCP, ENA).
• Viral PCR panels if recent infection is suspected.
• Allergen testing (rarely contributory).

Treatment Options

Management focuses on slowing progression, relieving symptoms, and treating underlying causes. No cure exists; treatment effectiveness varies.

1. Pharmacologic Therapies

• Systemic Corticosteroids: First‑line for acute exacerbations or early disease (prednisone 0.5–1 mg/kg/day). Long‑term use is limited by side‑effects.
• Immunosuppressants: Mycophenolate mofetil, azathioprine, or tacrolimus are used especially in post‑transplant OB to control immune‑mediated injury.
• Macrolide Antibiotics (e.g., azithromycin): Possess anti‑inflammatory properties; may improve lung function in some patients.
• Bronchodilators: Long‑acting beta‑agonists (LABA) or anticholinergics (LAMA) provide symptomatic relief but do not alter disease course.
• Antifibrotic agents: Nintedanib and pirfenidone are under investigation; presently approved for idiopathic pulmonary fibrosis but increasingly studied for OB.

2. Non‑Pharmacologic Interventions

• Pulmonary Rehabilitation: Structured exercise, breathing techniques, and education improve functional capacity and quality of life.
• Oxygen Therapy: For resting hypoxemia (SpO₂ < 90 %).
• Airway Clearance Techniques: Chest physiotherapy, oscillatory positive expiratory pressure devices, or high‑frequency chest wall oscillation to reduce mucus plugging.

3. Procedural Options

• Bronchoscopic Balloon Dilation or Stent Placement: For focal airway stenosis causing severe obstruction.
• Lung Transplantation: Considered in end‑stage disease when medical therapy fails and the patient meets transplant criteria.

4. Management of Underlying Triggers

• Discontinue exposure to offending chemicals or fumes.
• Optimise control of autoimmune disease with disease‑modifying agents.
• Adjust immunosuppression regimen after transplant in collaboration with a transplant pulmonologist.

Living with Obliterative Bronchiolitis

Chronic disease management is essential for preserving lung function and quality of life.

Daily Self‑Care

• Medication Adherence: Use inhalers and oral meds exactly as prescribed; keep a medication log.
• Vaccinations: Annual influenza vaccine, pneumococcal vaccination (PCV20 or PCV15 + PPSV23), and COVID‑19 boosters reduce infection risk.
• Breathing Exercises: Pursed‑lip breathing and diaphragmatic breathing can reduce dyspnea during activities.
• Physical Activity: Aim for 150 minutes of moderate aerobic exercise weekly, adjusted for tolerance.
• Environmental Controls: Use HEPA air cleaners, avoid smoke, pollutants, and strong fragrances.
• Hydration & Nutrition: Adequate fluid intake keeps secretions thin; a balanced diet supports immune function.

Monitoring & Follow‑Up

• Schedule pulmonary function testing every 3–6 months.
• Keep a symptom diary (e.g., peak flow, cough frequency) to detect early decline.
• Promptly report new or worsening symptoms to your pulmonologist.

Psychosocial Support

Living with a chronic lung disease can cause anxiety or depression. Consider counseling, support groups (e.g., Pulmonary Fibrosis Foundation), and mindfulness techniques.

Prevention

Because many cases are secondary to known triggers, preventive measures are practical.

• Occupational Safety: Use proper respiratory protective equipment (e.g., N95 or P100 respirators) when handling chemicals; follow workplace exposure limits.
• Avoidance of Smoke: Do not smoke; minimize second‑hand smoke exposure.
• Prompt Treatment of Respiratory Infections: Early antiviral or antibacterial therapy may reduce airway injury.
• Vaccination: As mentioned above, reduces infection‑related risk.
• Post‑Transplant Care: Strict adherence to immunosuppressive regimens and regular monitoring for early signs of BOS.

Complications

If untreated or poorly controlled, OB can lead to serious sequelae:

• Respiratory Failure: Progressive hypoxemia requiring long‑term supplemental oxygen or mechanical ventilation.
• Pulmonary Hypertension: Chronic hypoxia and vascular remodeling increase right‑heart strain.
• Cor Pulmonale: Right‑ventricular enlargement secondary to pulmonary hypertension.
• Frequent Respiratory Infections: Mucus stasis predisposes to bacterial colonisation and exacerbations.
• Reduced Quality of Life & Functional Decline: Inability to perform daily activities, leading to dependence.

When to Seek Emergency Care

References

• Mayo Clinic. Bronchiolitis Obliterans (Obliterative Bronchiolitis). Updated 2023.
• American Lung Association. Bronchiolitis Obliterans. Accessed May 2024.
• World Health Organization. Occupational exposures and respiratory diseases. 2022.
• National Institutes of Health, National Heart, Lung, and Blood Institute. Bronchiolitis Obliterans. 2023.
• Cleveland Clinic. Bronchiolitis Obliterans. Reviewed 2024.
• Wang, C. et al. “Management of Bronchiolitis Obliterans After Lung Transplantation.” Journal of Heart & Lung Transplantation, vol. 41, no. 6, 2022, pp. 655‑664.
• Fisher, J. et al. “Occupational Exposure to Diacetyl and the Risk of Obliterative Bronchiolitis.” Occupational and Environmental Medicine, 2021.